Risk of Posterior Staphyloma in Highly Myopic Europeans : From Epidemiology to Anatomy.
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 12 Feb 2026
- Expected to end
- Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- blood sampling for DNA
- Record updated
- 7 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Adults with high myopia (axial length ≥ 26.00 mm or degree of myopia of at least -6 diopters), with and without posterior staphyloma; Adults aged 18 years or over; Patient with high myopia (axial length ≥ 26.00 mm or degree of myopia of at least -6 diopters), with good quality retinal imaging; Patient who has signed a consent form to participate in the study; Patient who is a beneficiary of a social security scheme or who is entitled to it
Who cannot take part
- Any systemic or ocular pathologies with an impact on the posterior segment of the eye; Patient with a systemic pathology likely to affect the posterior segment of the eye:; Diabetes; Systemic inflammatory disease: sarcoidosis, rheumatoid arthritis, systemic lupus erythematosus, Horton's disease; Patients with retinitis pigmentosa; Patients with syndromic myopia; Patients with myopia associated with a genetic disease such as hereditary vitreoretinopathy; Patients under guardianship, curatorship or legal protection, as well as pregnant or breastfeeding women (article L1121-5 of the CSP)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
In this cross-sectionnal study the aim is to increase the understanding of posterior staphyloma through a unique European consortium. Therefore, all eligible patients that either visit the outpatient clinic at Radboud in Nimegen, the Netherlands, or visit University Hopital Puerta de HierroMajadahonda in Madrid, Spain, or visit University Hospital Cochin in Paris, France, and after consenting, will be included.
Read full original descriptionShow less
600 high myopic European cases are expecting. A standardized protocol in all centers in order to create a uniform dataset.
Besides the standard of care, blood samples will be collected.
All data collected will be stored in an onlie Castor database
The 2 groups in the trial
- AM A : High Myopia without myopic staphylomaTreatment being tested
Treatment: blood sampling for DNA
- ARM B : High myopia with myopic staphylomaExisting treatment, for comparison
Treatment: blood sampling for DNA
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 7 August 2026